scholarly journals Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib

Medicine ◽  
2021 ◽  
Vol 100 (39) ◽  
pp. e27385
Author(s):  
Koki Nakashima ◽  
Yoshiki Demura ◽  
Kosuke Kurokawa ◽  
Toshihiro Takeda ◽  
Norihiro Jikuya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Successful Treatment ◽  
Small Cell ◽  
Meningeal Carcinomatosis ◽  
Small Cell Lung ◽  
Alk Positive

Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer

Lung Cancer ◽  
2015 ◽  
Vol 88 (1) ◽  
pp. 112-113 ◽  
Author(s):  
Tomonobu Koizumi ◽  
Toshirou Fukushima ◽  
Toshiharu Tatai ◽  
Takashi Kobayashi ◽  
Nodoka Sekiguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Successful Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

scholarly journals 155P Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer

2021 ◽  
Vol 16 (4) ◽  
pp. S782
Author(s):  
I. Dogan ◽  
M. Gürbüz ◽  
N. Paksoy ◽  
F. Ferhatoğlu ◽  
S. Vatansever ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient

2020 ◽  
Vol 26 (8) ◽  
pp. 2031-2033
Author(s):  
Nilay Sengul Samanci ◽  
Emir Celik ◽  
Burak Akovalı ◽  
Sait Sager ◽  
Fuat Hulusi Demirelli
Keyword(s):  
Lung Cancer ◽  
Elderly Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Stage 4 ◽  
Alk Positive

Introduction Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule. Case report In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC). Management and outcome: She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event. Discussion Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.

scholarly journals The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer

2013 ◽  
Vol 8 (12) ◽  
pp. 1570-1573 ◽  
Author(s):  
Justin F. Gainor ◽  
Sai-Hong Ignatius Ou ◽  
Jennifer Logan ◽  
Lawrence F. Borges ◽  
Alice T. Shaw
Keyword(s):  
Lung Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Central Nervous System ◽  
Alk Positive

scholarly journals MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

2017 ◽  
Vol 12 (1) ◽  
pp. S378-S379 ◽  
Author(s):  
Young Kim ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masashi Kondo ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document